No abstract available
MeSH terms
-
Anaphylaxis / etiology
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / immunology
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Cetuximab / adverse effects
-
Cetuximab / immunology
-
Cetuximab / therapeutic use*
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Humans
-
Maintenance Chemotherapy / methods*
-
Male
-
Middle Aged
-
Neoplasms, Second Primary / drug therapy*
-
Neoplasms, Second Primary / radiotherapy
-
Neoplasms, Second Primary / surgery
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Palliative Care
-
Panitumumab / therapeutic use*
-
Progression-Free Survival
-
Randomized Controlled Trials as Topic
-
Research Design
-
Squamous Cell Carcinoma of Head and Neck / drug therapy*
-
Squamous Cell Carcinoma of Head and Neck / ethnology
-
Tongue Neoplasms / drug therapy*
-
Tongue Neoplasms / radiotherapy
-
Tongue Neoplasms / surgery
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Immunological
-
Panitumumab
-
Carboplatin
-
Paclitaxel
-
Cetuximab